Highlights of experts Celsus serious side effects of topical corticosteroids -
A 2013 Mayo Clinic study involving more than 140,000 patients have shown that skin disorders are the most common reason Americans seek nonacute and home health care. Topical corticosteroids, available since 1950, are the most prescribed medications and dermatological the mainstay of treatment for many conditions. According to IMS Health, which tracks prescription data, the total number of retail prescriptions for steroids increased from 171,300,000 in 07 to 207,0,000 in 2012, with topical steroids representing 39 million prescriptions.
A man with a view striking trend is Gur Roshwalb, MD, CEO of Celsus Therapeutics, a drug development company focusing on first-in-class non-steroidal synthetic drugs anti new drugs-inflammatory anti-inflammatory called multi-functional (MFAIDs). According to Dr. Roshwalb, prolonged use of steroids can cause unwanted side effects such as tachyphylaxis (tolerance to vasoconstriction), rosacea, stretch marks and skin atrophy. In addition, the small size and the suppression of the hypothalamic-pituitary-adrenal axis in children are of concern for physicians and patients. the use of long-term steroids may also promote the development of infections. To counter steroid treatment limitations, some doctors prescribed calcineurin inhibitors, which in turn carry a risk of cancer and can suppress the immune system.
The concerns of Dr. Roshwalb are taken up by the National Eczema Association, who notes that the frequent and prolonged application of a topical corticosteroid on the eyelids, for example, can cause glaucoma and even cataracts ; acne around the mouth; and redness around the hair follicles.
Dr. Determining Roshwalb to develop alternatives to topical corticosteroids is made possible by his own background and the work he is doing to Celsus. Before entering the business world, Dr. Roshwalb was in private practice in New York and certified in internal medicine. He received his MD from the Albert Einstein College of Medicine and trained in internal medicine at Mount Sinai Medical Center, where he also held the residency position in 1997-1998.
MFAIDs Celsus' are designed to block a key enzyme that triggers inflammation. lead drug candidate from the company, MRX-6, is a topical cream being tested in a phase II trial in atopic dermatitis, with results expected in the fourth quarter of 2014. A previous trial of MRX-6 showed significant improvement in patients with dermatitis contact. Celsus believes MRX-6 and other MFAIDs it is developing could offer an effective treatment for a wide range of diseases, noninflammatory in dermatitis, but also in lung inflammation such as cystic fibrosis, inflammatory disease of intestine and conjunctivitis.
If the work Celsus materializes, it could be the beginning of a new series of options for patients suffering from various types of inflammation and avoiding the very real risks of steroids to today.
EmoticonEmoticon